source
- Replimune's melanoma virus therapy wins FDA advisory committee vote after two rejectionsReplimune's oncolytic virus RP1, also called vusolimogene oderparepvec and Tudriqev, has been rejected twice by the FDA. Today an advisory committee voted 10 to 3 that the candidate shows enough ef…
- BMS CEO says firm not pressured to pursue acquisitions despite quiet M&A yearBMS chief executive Chris Boerner told analysts on the second‑quarter earnings call that the company’s robust late‑stage pipeline means it does not feel any compulsion to chase deals. The firm has…